Preventing Keloid Recurrence With SRT
August 27th 2021Part 2 of Dermatology Times®’ coverage of a strategic look at superficial radiation therapy (SRT) presented at the recent Music City SCALE Symposium for Cosmetic Advances & Laser Education 16th Annual Meeting details this therapy’s potential for reducing keloid recurrence.
SRT Shows Positive Outcomes for NMSC
August 25th 2021Part 1 of Dermatology Times®’ coverage of a strategic look at superficial radiation therapy (SRT) presented at the recent Music City SCALE Symposium for Cosmetic Advances & Laser Education 16th Annual Meeting in Nashville, Tennessee, showcases this therapy’s efficacy in treating keratinocytic skin cancers.
Managing pandemic patient volumes
October 15th 2020Since the start of the pandemic, dermatologists have seen an average 50% drop in patient volume. While teledermatology has offered a channel for non-urgent patients and patient visits are rebounding, overall patient volumes are still significantly lower than 2019.
Microbiome-based treatments not ready for prime time
August 26th 2020Manipulating the microbiome has been shown to impact conditions including acne, atopic dermatitis (AD), autoimmune diseases and melanoma. While there are many clinical trials now in progress, safety and efficacy have not yet been proven.
Emerging options for high-risk melanoma
August 26th 2020Recruiting is ongoing for an investigator-initiated clinical trial of pembrolizumab in clinical stage 2B/C melanoma which will investigate the effects of treatment with pembrolizumab before surgery to remove melanoma on the rate of positive sentinel lymph nodes in patients with stage IIB/C melanoma.
Inflammation-associated itching perceived as more intense
November 19th 2019A recent study showing that patients perceive inflammation-associated itch as more intense and qualitatively different than itch without inflammation suggests that dermatologists target inflammation in conditions such as atopic dermatitis.
Biologics make psoriasis clearance a real possibility
July 16th 2019“The landscape of biologics and biosimilars is changing rapidly, and for the better,” says Mark Lebwohl, M.D. Biologics have given patients the possibility of complete psoriasis clearance and control of their psoriatic arthritis (PsA), which were not options 20 years ago, adds Alice Gottlieb, M.D., Ph.D.